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ABSTRACT Personalised medicine aims to tailor medical decisions to the individual patient. A possible
approach is to stratify patients according to the risk of adverse outcomes such as exacerbations in chronic
obstructive pulmonary disease (COPD). Risk-stratified approaches are particularly attractive for drugs like
inhaled corticosteroids or phosphodiesterase-4 inhibitors that reduce exacerbations but are associated with
harms. However, it is currently not clear which models are best to predict exacerbations in patients with
COPD. Therefore, our aim was to identify and critically appraise studies on models that predict
exacerbations in COPD patients. Out of 1382 studies, 25 studies with 27 prediction models were included.
The prediction models showed great heterogeneity in terms of number and type of predictors, time
horizon, statistical methods and measures of prediction model performance. Only two out of 25 studies
validated the developed model, and only one out of 27 models provided estimates of individual
exacerbation risk, only three out of 27 prediction models used high-quality statistical approaches for model
development and evaluation. Overall, none of the existing models fulfilled the requirements for risk-
stratified treatment to personalise COPD care. A more harmonised approach to develop and validate high-
quality prediction models is needed to move personalised COPD medicine forward.
Introduction
Personalised medicine aims to tailor medical decisions to the individual patient [1, 2]. The interest in
personalised respiratory medicine has risen recently but it has not been introduced much into practice yet [3, 4].
For patients with chronic obstructive pulmonary disease (COPD) [5], a possible approach for personalising
medical treatments is to stratify patients according to the risk of exacerbations, in order to prescribe treatments
such as inhaled corticosteroids or phosphodiesterase-4 inhibitors only if their benefits in terms of reduced risk
of exacerbations [6] are expected to outweigh the harms [7–9]. For example, a recent benefit–harm assessment
of the phosphodiesterase-4 inhibitor roflumilast suggested that the risk for severe exacerbations requiring
hospital admissions needs to be at least 20% over 1 year so that the expected benefits (in terms of reducing
severe exacerbations) overcome the gastrointestinal, psychiatric and neurological side effects of roflumilast [7].
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REVIEW
COPD
Exacerbations are an ideal target for risk-stratified treatment since it is one of the most important
outcomes for COPD patients and avoiding them is likely to lead to a higher health-related quality of life,
longer life and less healthcare cost. However, a prerequisite for risk-stratified treatment is that the risk of
exacerbations can be accurately predicted by a prediction model [10–12] that has been thoroughly
developed and validated [13–16]. A number of models predicting exacerbations in COPD patients have
been published reporting on combinations of information from patient history, clinical characteristics and
test results including biomarkers to predict exacerbations. It is still not clear yet, though, which prediction
model predicts exacerbations most accurately and is applicable in daily practice. For this reason, along
with the lack of other systematic reviews, the aim of this systematic review was to identify and critically
appraise studies presenting models predicting exacerbations in COPD patients that may support
risk-stratified and personalised treatment.
Materials and methods
The authors followed the Center for Reviews and Dissemination guidance for the methodology [17] and
the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for the
reporting [18, 19].
Protocol
We wrote a detailed study protocol in advance (supplementary material). We carefully followed the
protocol and recorded any deviations from it.
Search methods
We identified eligible papers through a search of the databases Medline (from 1949), Embase (from 1974)
and Scopus (from 1996). The search was performed by an information specialist of the University of Zurich
(Zurich, Switzerland). Additional studies were identified through the Pubmed-related articles function and
reference list of included studies, author contacts, narrative reviews or the “grey” literature (reports,
dissertation, conference abstracts or papers).
Participants
To be eligible for inclusion, patients were required to have a COPD diagnosis according to Global
Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (i.e. the ratio between forced expiratory
volume in 1 s (FEV1) and forced volume capacity (FVC) had to be <0.7 after bronchodilation).
Outcome definition
The outcome of interest was exacerbation. Exacerbations could be event based (e.g. course of antibiotics
and/or oral corticosteroids or admission to hospital) or symptom based (patient-reported change in
symptoms with or without use of diary charts).
General selection criteria
Publication status, year of publication and language were not subject to exclusion criteria.
Study design
We included studies with a longitudinal design (prospective or retrospective cohorts) or control arms of
randomised control trials (that can be regarded as cohort studies). Length of follow-up was not subject to
exclusion criteria.
Selection criteria for prediction models
For inclusion, the analysis section of the paper had to refer to a prediction model [10] or multivariable
association [20, 21] of a set of predictors with the outcome exacerbation. By also including multivariable
models without explicit reference to prediction models, we broadened the eligibility of models substantially
in order to learn as much from the literature as possible. But in order to foresee the use of such
multivariable models, which often focused on a single predictor of interest (e.g. a biomarker), while
adjusting for other predictors (e.g. previous exacerbations or FEV1 % predicted), a requirement for inclusion
was that the model also included four commonly used and easily available predictors (i.e. previous
exacerbations, smoking, age, and FEV1 % pred) beside the predictor of interest. Indeed, analyses not
accounting for these four common predictors may over-estimate the predictive value of a particular single
predictor (such as a biomarker) and there is general consensus that the use of more sophisticated predictors
is justified only if they provide additional value when added to commonly available predictors. A further
requirement for the inclusion in the systematic review was the presence of at least one performance of the
prediction model (e.g. area under the curve (AUC) for discrimination). If information needed to decide on
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inclusion was not available from the papers we contacted the authors up to two times to obtain them. The
studies could also be included if exacerbation was not the only outcome of the study.
Procedure
Two review authors (B. Guerra and C. Bianchi) independently assessed titles and abstracts of all references
retrieved. Two review authors (B. Guerra and V. Gaveikaite) independently reviewed full-text versions of
potentially relevant studies, and selected the studies. Disagreement was resolved by discussion between the
two review authors. If consensus was not reached, a third review author was consulted (M.A. Puhan).
Data extraction and management
Two review authors (B. Guerra and V. Gaveikaite) independently extracted the following data from
included studies: demographic characteristics of the study population, disease severity, clinical settings,
definition of the outcome, duration of the follow-up, details of the statistical method as well as of the
predictors of the final model. All missing information was searched for in the references indicated in the
papers (if available), or asked for by email to the authors. Some missing information was retrieved from
pharmaceutical companies involved in the studies (if needed, by formal requests).
Quality assessment concerned six categories of potential bias (participant selection as shown in the study flow,
measurement of predictors, measurement of outcome (i.e. exacerbation), statistical analysis for model
development, performance measures and validation, based on guidance from Cochrane [22], an early version of
the prediction study risk of bias assessment tool (PROBAST) guidelines (www.systematic-reviews.com/probast)
and the needs of this particular systematic review. The criteria for rating studies at low, high or unclear risk of
bias as well as a description for each bias category of each included study are shown in the supplementary
material.
Some studies reported on small variations of the same prediction model. Since these models performed in
general very similarly, we considered one prediction model per study for the main analysis (supplementary
material). We only considered more than one prediction model per study if they were substantially
different, as in ALMAGRO et al. [23], where the predictive performance of the CODEX (comorbidity,
obstruction, dyspnoea and severe exacerbations), ADO (age, dyspnoea and airflow obstruction) and
BODEX (body mass index, airflow obstruction, dyspnoea and severe exacerbations) indices were assessed
(thus, we will speak in this systematic review of 25 studies and 27 prediction models).
In order to evaluate the readiness of the prediction models for practice we defined a priori three criteria for
the clinical applicability of the models. 1) Availability predictors. We deemed the set predictors in each
prediction model to be easily (E) available if most of them were based on questions or information from
medical charts, to be moderately (M) available if some (at least two) were based on tests routinely done in
non-specialised and specialised settings and to be difficult (D) to be available if at least one of the predictor
was based on a test usually performed in specialised settings only (details concerning the assessment are
explained later in the text and in the supplementary material). 2) External validation. In order to be
confidently used in practice, prediction models require validations in populations other than the populations
in which it was developed [13, 14, 24]. We had high confidence in the performance if the model had been
validated (with a small decrease of performance between derivation and validation cohort) in an external
cohort of COPD patients and, accordingly, low confidence if an external validation was lacking. 3) Practical
applicability. To be useful for risk-stratified treatment in practice we deemed models to be useful if they
provided a simple point system like the BODE (body mass index, airflow obstruction, dyspnoea and exercise
capacity) or ADO indices (e.g. [25, 26]) with corresponding risks of exacerbations (e.g. 4 points=25%
probability of exacerbation for a specified time horizon), an online calculator or other means to easily derive
the risk of exacerbations for an individual patient. We deemed prediction models not ready for risk-stratified
treatment yet if only the statistical methods (e.g. regression coefficients) were reported.
Statistical analysis
Given the heterogeneity of the studies we deemed meta-analyses not a sensible approach and reported the
findings using descriptive summary statistics.
Results
Selection of studies
Figure 1 shows the study selection process and the main reasons for exclusion at the different stages. From
the database searches, we included 20 from a total of 1345 studies. From additional searches we included
another five studies and thus a total of 25 papers [23, 27–50] reporting on 27 prediction models
(supplementary material for details concerning each stage of the selection process).
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Study characteristics
The included studies were conducted in countries around the world (table 1). They are ordered according
to categories of exacerbation incidence. Acknowledging the lack of standard in literature for the individual
cut-off value (or more cut-off values) for the frequent exacerbator phenotype, and given the commonly
used cut-off of 2 exacerbations per person-year [36, 53] we categorised each cohort as low (<1 exacerbation
per person-year), moderate (1–2 exacerbations per person-year) or high (⩾2 exacerbations per person-year)
incidence of exacerbations. Three cohorts with high incidence of exacerbations, four cohorts with moderate
incidence of exacerbations and 19 cohorts with low incidence of exacerbations were included (for one of the
27 cohorts, the related data were not retrieved). Sample sizes ranged from 109 to 8020. The definition and
measurement of exacerbations was symptom-based in seven (out of 27 cohorts: 25 derivation cohorts plus
two validation cohorts), event-based in 17 and unclear definition in three cases. Exacerbations were not
adjudicated by a committee in any study. The prediction models were mainly based on prospective cohort
studies (control arm of a randomised controlled trial for one model [30]), while two prediction models were
based on retrospective cohort studies [28, 46]). Follow-up periods ranged from 14 days to up to 9 years (the
most common follow-up was up to 1 year). 21 out of the 25 included studies had the explicit aim to find a
combination of predictors strongly associated with exacerbations, while four studies [35, 37, 49, 50] focused
on a particular predictor but adjusted for age, FEV1 % predicted, smoking and previous exacerbation
(making them eligible for the inclusion in this review).
Predictors included in the prediction models
More than 50 different predictors were used across the included prediction models (supplementary
material). Airways obstruction (FEV1 % predicted or FEV1 or GOLD stage) was the most common
predictor (12 times out of 27 models). The next most common predictors were previous exacerbations
(nine times), age (nine times), smoking (eight times) and health-related quality of life (eight times). More
than half of predictors were included only once.
Quality assessment
21 out of 25 studies reported with low risk of bias on the study flow and the selection of participants
(figure 2), 23 out of 25 studies were deemed at low risk of bias for how they measured the predictors and
22 out of 25 studies were deemed at low risk of bias for how they measured exacerbations (given our
broad definition of exacerbation). 14 studies were at low risk of bias for how the prediction models were
developed statistically and how the statistical analysis was performed (the remaining 11 were at high risk).
Six studies were at low risk of bias in terms of the performance measures used (while 19 studies were at
high risk). 19 studies out of 25 were of good quality concerning the clinical data (i.e. the three bias
categories selection, definition and measurement of predictors and outcomes and in terms of how patients
were selected). Three out of 25 models were of good quality from a statistical point of view (i.e. the two
categories statistical method and performance evaluation). Finally, two studies [28, 30] performed an
internal validation [54] and two studies [23, 29] an external validation (other studies had a validation
cohort, but they made a prediction for other outcomes or they did not provide any performance measure
for the outcome exacerbation).
Electronic database search
n=1345
Pubmed related article search, references, reviews, grey literature
n=82
Number of studies after duplicates removed
n=1382
Excluded on abstract
n=1073
Included for full-text assessment
n=309
Included
n=25
Excluded on full-text assessment
Reason for exclusion:
  Not a prediction model (n=96)
  Different outcome (n=56)
  Not a primary study (n=42)
  Not the wanted study design (n=32)
  Others (n=58)
Total: n=284
FIGURE 1 Prediction models or multivariable association of a set of predictors with the outcome exacerbation.
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TABLE 1 Study characteristics
Studies by incidence of
exacerbation
Country Care setting Cohort study Patients# Mean age
years
Mean FEV1
% pred
Males % Definition of
exacerbation
Follow-up
years
Events in the
analysis
Person-years
of follow-up
Incidence
exacerbations
per year per
person
Low
BERTENS [29] Netherlands Outpatient
primary care
Prospective 243/240 73 71 68 Event-based up to 2 >70 (70 patients with
⩾1 event)
480 >0.15
BERTENS [29] (validation) Netherlands Outpatient
primary care
Prospective 793/793 67 71 53 Event-based up to 2 >222 (222 patients
with ⩾1 event)
1586 >0.14
PARSHALL [47] UK Outpatient
primary care
Prospective 309/127 70 50 56 Symptom-based¶ up to 1 >98 (98 patients with
⩾1 event)
127 >0.77
MOTEGI [43] Japan Outpatient
secondary care
Prospective 232/183 71 56 93 Symptom- and
event-based
up to 2 193 366 0.53
ALMAGRO [23] Spain Outpatient
secondary care
Prospective 679/606 73 45 90 Event-based up to 0.25
and 1
>98 (98 exacerbators
to 3 months of
follow-up period; data
from [51])
139.3 >0.70
ALMAGRO [23] (validation) Spain Outpatient
secondary care
Prospective 395/377 72 41 94 Event-based 1
JONES [38] England Outpatient
secondary care
Prospective 297+/
175§
67 42 71 Symptom-based up to 9 50 1575 0.03
SUETOMO [48] Japan Outpatient
secondary or
tertiary care
Prospective Not
reported/
123
67 64 87 Symptom-basedƒ up to 1 106## 123 0.87
MÜLLEROVA [45] 12 countries Secondary and
tertiary care
Prospective 2164/
2138
63 48 65 Event-based up to 3 1452 5725¶¶ 0.25
THOMSEN [50] Denmark Outpatient
tertiary care
Prospective++ 8020/
6574
67 80 47 Event-based 4 (median) 3083 26296 0.12
MOBERG [42] Denmark Outpatient
tertiary care
Prospective 695/674 69 37 36 Unclear 5.5 (mean) >421 (421 patients
with ⩾1 event)
3822§§ >0.11
ONG [46] Singapore Outpatient
tertiary care
Retrospective 127/127 71 44 91 Symptom-based 1.35
(mean)
318 (calculated using
mean number of
admissions (2.5))
171ƒƒ 0.08
TAKAHASHI [49] Japan Outpatient
tertiary care
Prospective 109/93 73 55 100 Symptom-based up to 1 92### 93 0.88
FAGANELLO [33] Brazil Outpatient
tertiary care
Prospective 120/120 65 61 71 Event-based up to 1 >95 (32 (27%)
patients with 1
episode, 21 (18%)
with 2 episodes, 7
(6%) with ⩾3
episodes of
exacerbation)
120 >0.79
GARCIA-AYMERICH [34] Spain Out- and
inpatient
tertiary care
Prospective 346/312 69 36 92 Symptom-based 1.1 (mean) >197 (63% of the
patients (197) with ⩾1
event)
343 >0.57
KO [39] China Inpatient
tertiary care
Prospective 327/243 74 52 86 Event-based up to 3 >186 (186 patients
with ⩾1 readmission
for AECOPD)
729 0.26
BRUSSE-KEIZER [30] Netherlands Inpatient
tertiary care
Control arm
of RCT
121/121 65 58 84 Event-based up to 1 >62 (31 patients with
⩾2 events)
121 >0.51
ECHAVE [32] Spain Inpatient
tertiary care
Prospective 120/93 71 43 89 Event-based up to 1 >61 (61 patients with
⩾1 event)
93 >0.65
Continued
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TABLE 1 Continued
Studies by incidence of
exacerbation
Country Care setting Cohort study Patients# Mean age
years
Mean FEV1
% pred
Males % Definition of
exacerbation
Follow-up
years
Events in the
analysis
Person-years
of follow-up
Incidence
exacerbations
per year per
person
GUDMUNDSSON [35] Sweden,
Norway,
Finland,
Iceland,
Denmark
Inpatient
tertiary care
Prospective 416/406 69 34 49 Event-based up to 1 >246 (246 patients
with ⩾1 readmission;)
406 >0.61
AMALAKUHAN [28] USA Retrospective Not
reported/
106
Unclear (presumably
event-based)
up to 1 >100 (50 patients with
⩾2 events)
106 >0.94
Moderate
LEE [40] China,
Taiwan,
Korea,
Australia
Outpatient
secondary or
tertiary care
Prospective 545/495 69 47 88 Symptom-based up to 0.5 >338 (338 patients
with ⩾1 event; 226
had instead ⩾1
moderate-to-severe
exacerbation)
247.5 >1.37
MOY [44] USA Outpatient
secondary or
tertiary care
Prospective 173/167 71 54 99 Event-based¶¶¶ 1.25
(mean)
263¶¶¶ 210 1.25
MARIN [41] Spain Outpatient
tertiary care
Prospective 275/275 65 49 100 Event-based 5.1
(median)
2735 (incidence
multiplied by
person-years)
1402+++ 1.95
HURST [36] 12 countries Inpatient
tertiary care
Prospective 2164/
2138
63 48 65 Event-based up to 3 6927 (incidence
multiplied by
person-years)
5725§§§ 1.21
High
CHEN [31] Taiwan Outpatient
secondary care
Prospective 150/143 72 49 73 Event-based 14 daysƒƒƒ 31 5.5 5.65
JACOB [37] Canada Outpatient
secondary or
tertiary care
Prospective 115/115 67 43 47 Event-based 1.5 (mean) 683 (incidence
multiplied by
person-years)
207 3.30
ALMAGRO [27] Spain Inpatient
tertiary care
Prospective 156/129 72 36 93 Event-based 1 335 (incidence
multiplied by
person-years)
129 2.60
Where data are not displayed, they were not reported and/or not straightforward to evaluate. The incidence of exacerbations category is indicated as low, moderate or high when the
exacerbation rate is <1 exacerbation per person-year, between 1 and 2 exacerbations per person-year or >2 exacerbations per person-year, respectively. Age and forced expiratory
volume in 1 s (FEV1) % pred refer to the mean in the study population. RCT: randomised controlled trial; AECOPD: acute exacerbations of chronic obstructive pulmonary disease.
#: number of patients in cohort/number of patients in analysis; ¶: slightly different data are provided for the other outcome analysed in the paper (healthcare use); +: data from [52]; §: for
which dyspnoea, obstruction, smoking and exacerbation index scores were available; ƒ: the outcome hospital readmission for exacerbation was also analysed in the paper; ##: obtained
from the data event per patients in each of the two categories (high chronic obstructive pulmonary disease (COPD) assessment test group and low COPD assessment test group);
¶¶: proxy considering the patients included in the analysis (2138) and those completing the 3 years of follow-up (1679); ++: from a population-based cohort a subgroup of individuals with
COPD was randomly selected; §§: obtained multiplying the number of patients in the study by the mean follow-up; ƒƒ: calculated using the mean follow-up value; ###: proxy obtained using
the mean exacerbation frequency per year in the two categories (normal IgG-titer and high IgG-titer); ¶¶¶: two different outcomes analysed (number of acute exacerbations and
COPD-related hospitalisation), only the data for the outcome acute exacerbations are presented; +++: proxy obtained from the median value for the follow-up; §§§: proxy considering the
patients included in the analysis (2138) and the ones completing the 3 years of follow-up (1679); ƒƒƒ: a follow-up of 3 months was also analysed in the paper.
https://doi.org/10.1183/16000617.0061-2016
6
C
O
P
D
|
B
.G
U
ER
R
A
ET
A
L.
Statistical methods
Table 2 shows a description of the 27 prediction models ordered by underlying statistical method (the
details of the two validation cohorts are shown as well, for a total of 29 rows); some papers included
different analyses, in one case [40] different statistical methods were shown; in order to avoid confusion
for the reader, we have included in table 2 only one statistical method per study, apart from those already
discussed [23] (where we included the three indices as three independent prediction models). The most
common statistical method was logistic regression (11 out of 25 different statistical methods analysed)
followed by Cox regression (10), and correlation analysis between an index (or a multivariable regression
equation) with the outcome (three). Finally, Poisson regression model, negative binomial regression model
and random forest model were each used once.
Most of the prediction models (18 out of 27) were directly presenting a model with a predefined index or
regression equation with predefined predictors. The remaining nine prediction models used some selection
procedure of the variables (i.e. univariable selection process relying on p-values, stepwise selection process
relying on p-values, combinations of both or selection process driven by the AUC).
For five prediction models (out of 27), performance related to both discrimination (e.g. AUC) and
calibration (e.g. Hosmer–Lemeshow test) were reported (in [29] this is true for both derivation and
validation cohort). A measure of discrimination (always AUC) was the most common performance provided
(21 times out of 27 prediction models). Measures of overall performance (like R2 or log-likelihood) and of
calibration (Hosmer–Lemeshow p-value or Chi-squared) were less common (provided, respectively for 12,
three, six and five models). The performance measure provided for the two validation cohorts are the same
than the ones for their respective derivation cohorts.
Clinical applicability of the models
The use of prediction models in practice needs to balance the clinical availability of predictors, i.e. the
effort to obtain the information, the easiness with which doctors can obtain a risk for the individual
patients and the predictive performance of the models. Ideally, predictors would be easily available, the
model easy to obtain individual probabilities from, and the model would predict the risk of exacerbations
accurately as shown by an external validation.
Table 3 shows the assessment of the readiness of the prediction models for clinical practice. The availability
of predictors was based on the assessment of the availability of single predictors and how many of them
were in different categories of availability (as shown in the online material, ‘1’ refers to a simple test or
simple questions or medical charts, ‘2’ refers to routine tests, ‘3’ refers to specialised tests). 12 out of 27
models were deemed to have an easily available set of predictors across non-specialised and specialised
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TABLE 2 Description of prediction models ordered by underlying statistical method
First author [ref.] Statistical method Follow-up years Outcome of the
prediction model
Derivation/
validation
Procedure for
variable selection
Initial
predictors n
Final
predictors n
Measure of
association
AUC (95%CI) HL
Chi-squared
HL p-value R2 log2
likelihood
PARSHALL [47] Correlation analysis up to 1 Exacerbation
(symptom-based)
(healthcare use also
analysed)
Derivation Predefined variables# 1 0.65–0.70# 0.355–0.974# 0.043–0.081#
MARIN [41] Correlation analysis 5.1 (median) Outpatient-treated
exacerbation
(hospitalisation also
analysed)
Derivation Predefined index 1 OR 0.78 (0.73–0.84) 0.31
JONES [38] Correlation analysis up to 9 Hospital admission for
exacerbation
Derivation Predefined index 1 0.755¶
CHEN [31] Logistic regression 14 days+ Hospital readmission
for exacerbation
Derivation Predefined variables 9 OR 0.10 139.49
ALMAGRO [27] Logistic regression up to 1 Hospital readmission
for exacerbation
Derivation Univariable selection 6 3 OR 1.9964 0.8496 0.146–0.194§
BRUSSE-KEIZER [30] Logistic regression up to 1 Patient with ⩾2
exacerbations
Derivationƒ Univariable and
stepwise selection
15 2 OR 0.717 (0.595–0.839) 7.512 0.483 0.099–0.15§
FAGANELLO [33] Logistic regression up to 1 Exacerbation Derivation Predefined index 1 OR 0.69##
SUETOMO [48] Logistic regression up to 1 Exacerbation (hospital
readmission for
exacerbation also
analysed)
Derivation Predefined variables 3 3 OR 0.77
TAKAHASHI [49] Logistic regression up to 1 Patient with ⩾2
exacerbations
Derivation Predefined variables 11 RR 0.81 66.64 0.56 0.22
HURST [36] Logistic regression up to 1 Increased
exacerbation
frequency
Derivation Stepwise selection 31 5 OR 0.22
BERTENS [29]
(derivation)
Logistic regression up to 2 Patients with ⩾1
exacerbation
Derivation Backward stepwise
selection
6 4 OR 0.75 (0.69–0.82) 8.66 0.37 0.26
BERTENS [29]
(validation)
Not expected up to 2 Patients with ⩾1
exacerbation
Validation Not expected Not expected Not expected Not expected 0.66 (0.62–0.71) 32.98 0.00 0.09
MOTEGI [43] Logistic regression up to 2 Exacerbation Derivation p-value selection 14 2 OR 0.76–0.78++ 0.15–0.18++
THOMSEN [50] Logistic regression up to 1§§ Frequent exacerbator
(⩾2 exacerbations >1
year apart)
Derivation Predefined variables 8–11ƒƒ OR 0.71–0.73ƒƒ
LEE [40] Logistic regression up to 0.5 Any exacerbation
(moderate–severe
exacerbation (logistic
regression) and time
to first exacerbation
(Cox regression) also
analysed)
Derivation Predefined variables 1–9### RR 0.64–0.79###
ALMAGRO [23]
(derivation;
CODEX)
Cox regression up to 1¶¶¶ Hospital readmission
for exacerbation
Derivation Predefined index 1 HR 0.583
ALMAGRO [23]
(derivation;
ADO)
Cox regression up to 1¶¶¶ Hospital readmission
for exacerbation
Derivation+++ Predefined index 1 HR 0.533
ALMAGRO [23]
(derivation;
BODEX)
Cox regression up to 1¶¶¶ Hospital readmission
for exacerbation
Derivation+++ Predefined index 1 HR 0.633
ALMAGRO [23]
(validation;
CODEX)
Not expected up to 1 Hospital readmission
for exacerbation
Validation Not expected Not expected Not expected Not expected 0.590
ECHAVE-SUSTAETA [32] Cox regression up to 1 Hospital readmission
for exacerbation
Derivation Univariable and
stepwise selection
6 2 HR 0.7601 0.334
GUDMUNDSSON [35] Cox regression up to 1 Hospital readmission
for exacerbation
Derivation Predefined variables Unclear 5 HR 2175.6
Continued
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TABLE 2 Continued
First author [ref.] Statistical method Follow-up years Outcome of the
prediction model
Derivation/
validation
Procedure for
variable selection
Initial
predictors n
Final
predictors n
Measure of
association
AUC (95%CI) HL
Chi-squared
HL p-value R2 log2
likelihood
GARCIA-AYMERICH [34] Cox regression 1.1 (mean) Hospital readmission
for exacerbation
Derivation Univariable selection 23 7 HR 0.71
JAKOB [37] Cox regression 1.5 (mean) Any exacerbation
(outpatient-treated
and inpatient treated
exacerbations also
analysed)
Derivation Predefined variables 7 RR 833.372§§§
MÜLLEROVA [45] Cox regression up to 3 Hospital admission for
exacerbation
Derivation Predefined variables Unclear 6 HR 0.742 (0.718–0.766)ƒƒƒ 5.57ƒƒƒ 0.696ƒƒƒ 0.15ƒƒƒ
KO [39] Cox regression up to 3 Hospital readmission
for exacerbation
Derivation Predefined index 1 HR 0.58####
MOBERG [42] Cox regression 5.5 (mean) Hospital admission for
exacerbation
Derivation Univariable selection Unclear 18 HR 0.62 (0.59–0.65)
ONG [46] Poisson regression 1.35 (mean) Hospital Admission
for exacerbation
Derivation Predefined index 1 IRR 0.16¶¶¶¶
MOY [44] Negative binomial
regression
1.25 (mean) Exacerbation (hospital
readmission also
analysed)
Derivation Predefined variables 4–5++++ Rate ratio 0.59–0.62++++
AMALAKUHAN [28] Random forest up to 1 Hospital readmission
for exacerbation
Derivation§§§§ Variables of
importance evaluated
with AUC
60 5 0.75ƒƒƒƒ
In this table only the data and analyses related to one outcome (in general the one deemed to be closer to the definition of exacerbation) are reported, with exception of [23], for which
three different rows (for the three different predefined indices: CODEX (comorbidity, obstruction, dyspnoea and severe exacerbations), ADO (age, dyspnoea and airflow obstruction) and
BODEX (body mass index (BMI), airflow obstruction, dyspnoea and severe exacerbations)) are used. Where data are not displayed, they were not reported and/or not straightforward to
evaluate. The number of initial predictors is often a proxy we have evaluated. AUC: area under the curve; HL: Hosmer-Lemeshow test; OR: odds ratios; RR: relative risk; HR: hazard
ratios; IRR: incidence rate ratios.
#: four-domain subscales of the Medical Outcomes Study short-form health survey (36 items) (general health perceptions, mental health, role limitation-physical, correlated
mental-health score) were evaluated as separated prediction models; ¶: performance refers to the DOSE (dyspnoea, obstruction, smoking and exacerbation frequency) index (a
performance was also discussed for Medical Research Council Dyspnoea Scale and forced expiratory volume in 1 s % pred); +: follow-up of 3 months also analysed;
§: Cox-Snell-Nagelkerke definition of R2; ƒ: to assess over-fitting jackknife cross validation technique was applied to the prediction rule; ##: performance refers to the BODE (BMI, airflow
obstruction, dyspnoea and exercise capacity) index (a performance for Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage is also provided) and other multivariable
models are also shown but no performance was provided; ++: according to the model used (four different ones are presented); §§: the supplementary material of the study reports the
data for a median follow-up of 4 years (range of performances with and without the three biomarkers evaluated in the study: 0.92–0.92); ƒƒ: according to the inclusion in the final model of
three inflammatory biomarkers as predictors, net reclassification index used to evaluate (40%; 22–57%) the improvement in performances with the inclusion of the three biomarkers;
###: according to if chronic obstructive pulmonary disease (COPD) assessment test was categorised or not and if there was or not adjustment for other variables (age, BMI, duration of
COPD, current smoking status, number of comorbidities, history of influenza vaccination, country); ¶¶¶: for the derivation cohort the follow-up of 3 months was also analysed;
+++: validation was performed but no performance was provided; §§§: Akaike information and Schwarz-Bayes criteria also provided, but not reported here; ƒƒƒ: data provided upon request
by the authors; ####: performance refers to the BODE index (a performance for the BODE’s 4-component was also provided); ¶¶¶¶: performance refers to the BODE index (a performance
for GOLD stage was also provided); ++++: different models evaluated (Step_CRP, STEP_IL-6 or BODE); §§§§: internal validation performed; ƒƒƒƒ: mean AUC for 200 runs.
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healthcare settings, four out of 27 to have an moderately easy available set of predictors and 11 out of 27 to
have a set of predictors whose data is difficult to obtain across healthcare settings. Only two models [23, 29]
can be confidently used in other populations because an external validation was performed to assess the
transportability of the prediction model [24]. Also, only one study [27] provided a way to easily obtain an
estimate of the risk of an exacerbation for an individual patient and thus a basis for risk-stratified treatment.
Overall, none of the existing models fulfilled all criteria for being ready for clinical application and use for
risk-stratified treatment to personalise COPD care.
Discussion
Our systematic review identified 25 studies reporting on 27 statistical prediction models for exacerbation in
patients with COPD. The prediction models differ greatly in terms of how they were developed and which
predictors and measures for their predictive performance were used. Most studies were of good quality
concerning the clinical settings and tests (i.e. selection, definition and measurement of predictors and
outcomes and in terms of how patients were selected). However, most of the prediction models were at
high risk of bias because unsound statistical methods to develop prediction models, and a lack of
validation. The overall assessment of readiness of the 27 prediction models for use in practice showed that
none were ready for clinical application.
Strengths and limitations
The strengths of this systematic review were the adherence to rigorous systematic review methodology and
reporting guidelines, apart from a thorough search strategy and a great effort for retrieving the needed
information from the authors. A limitation could be considered the broad inclusion criteria concerning the
TABLE 3 Readiness of prediction models for clinical practice
First author [ref.] Availability predictors External validation Practical applicability
BERTENS [29] Easy Yes No
ALMAGRO [23] Easy Yes No
ALMAGRO [23] Easy Yes No
ALMAGRO [23] Easy Yes No
ALMAGRO [27] Difficult No Yes#
BRUSSE-KEIZER [30] Easy No¶ No
AMALAKUHAN [28] Easy No+ No
JONES [38] Easy No§ No
ECHAVE-SUSTAETA [32] Easy No No
JAKOB [37] Easy No No
MOTEGI [43] Easy No No
LEE [40] Easy No No
PARSHALL [47] Easy No No
CHEN [31] Medium No No
GUDMUNDUSSON [35] Medium No No
HURST [36] Medium No No
SUETOMO [48] Medium No No
FAGANELLO [33] Difficult No No
KO [39] Difficult No No
ONG [46] Difficult No No
GARCIA-AYMERICH [34] Difficult No No
MARIN [41] Difficult No No
MOBERG [42] Difficult No No
MOY [44] Difficult No No
MÜLLEROVA [45] Difficult No No
TAKAHASHI [49] Difficult No No
THOMSEN [50] Difficult No No
Availability predictors refers to how easy it is to obtain the data related to the predictors. External validation
refers to the reliability of the model in terms of comparison of performance between derivation and eventual
validation cohort. Practical applicability indicates if it is easy to extract individual likelihoods of exacerbation
from the model. Studies presenting different models are considered only once, with exception of ALMAGRO et al.
[23] for which different predefined indices are shown. #: the paper explains how to you can obtain probabilities
starting from the logistic regression equation and indicates how to calculate individual probabilities starting
from the predictors; ¶: the jackknife cross validation was applied but no performance was indicated; +: internal
validation was applied but no performance is indicated; §: validation was performed for other outcomes.
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definition of exacerbation, potentially introducing heterogeneity among models. Furthermore, the adopted
broad definition of prediction model could have allowed the inclusion of studies not meant to concern
prediction, but only evaluating the association of an index (or a multivariable regression equation) with
the outcome. Nevertheless, we deemed our broader approach suitable in order not to miss prediction
models that may be useful for clinical practice. Finally, the big heterogeneity of statistical methods used in
literature makes probably not valuable to overall compare all the models even if they are providing the
same performance measure (e.g. AUC), since they are often too different in terms of definition of
exacerbations, time horizon, statistical method and outcome of the prediction model.
Future research
In order to come up with high-quality prediction models for exacerbations in COPD patients, a standard
methodology for developing the models should be adopted [55]. For instance, in certain medical fields, some
indices were validated and are currently used in clinical setting for risk-stratified prevention and treatment.
The cardiovascular field, for example, has a long tradition that started with the Framingham Risk Score
predicting the risk of cardiovascular disease [56] and led to clinical guidelines that heavily rely on
risk-stratified prevention of cardiovascular disease [57, 58]. In COPD, high-quality prediction models, for
example the BODE and ADO indices, have been developed and externally validated for the outcome of
mortality [25, 26, 59]. There is also a research need to better understand how prediction models could be
made as attractive as possible to use in practice. The optimal balance between availability of predictors,
practical applicability and predictive measurement properties is not yet well understood [60, 61]. It is
paramount that prediction models are validated thoroughly in order to make sure that the risk predictions
are accurate across different populations and could be used with confidence for risk-stratified treatment
[14, 24]. Finally, it would be ideal if the COPD community agreed on a single or very few different
exacerbation prediction models since validations and implementation research are more efficient if there is a
common prediction model compared with having many different prediction models [62]. Such a prediction
model can always be improved by opportunely updating it (if necessary) in new cohorts [10, 63] and by
adding promising predictors, but it needs to build upon prior knowledge on other datasets. Of course,
separate models are justified if the decisions they inform are distinct, for example, in terms of time horizon.
Conclusions
Overall, none of the existing prediction models fulfilled the criteria for being ready for clinical application
and use for risk-stratified treatment to personalise COPD care. The available COPD cohorts contain relevant
populations, predictors and exacerbation measurements but a more harmonised approach to develop and
validate high-quality predictions is needed to move personalised COPD medicine forward.
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